ROSALIND ADVISORS INC
Q1 2025 Form 13-F

TORONTO, ONTARIO, CANADA
CIK 0001622627 · Institutional investment manager
$205.6M Reported Value Total
Reported value
$205.6M
Quarter over quarter
+1.2%
Holdings
31
Top-10 concentration
63.4%

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Steven Salamon
President, Rosalind Advisors, Inc.

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2025 13F record

Q1 2025 13F filing summary

Q1 2025 Form 13F portfolio summary
Period of report March 31, 2025
Filed May 14, 2025
Form 13F-HR
Reported value $205.6M
Positions 31
Change in reported value +5.2%
New positions 7
Exited positions 4
Position turnover 31.4%
Top-10 concentration 63.4%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
35 $311.9M
Q2 2026 13F
Filed Aug 14, 2026
29 $269.2M
Q1 2026 13F
Filed May 14, 2026
32 $248.9M
Q4 2025 13F
Filed Feb 12, 2026
29 $284.5M
Q3 2025 13F
Filed Nov 13, 2025
29 $292.6M
Q2 2025 13F
Filed Aug 14, 2025
29 $210.9M
Q1 2025 13F
Filed May 14, 2025
31 $205.6M
Q4 2024 13F
Filed Feb 11, 2025
28 $195.6M
Q3 2024 13F
Filed Oct 30, 2024
29 $156.2M
Q2 2024 13F
Filed Jul 12, 2024
35 $130.0M
Q1 2024 13F
Filed Apr 25, 2024
31 $107.0M
Q4 2023 13F
Filed Feb 14, 2024
27 $121.4M

Top 20 holdings · Q1 2025

Largest Q1 2025 13F positions by reported value
# Holding Reported value % of portfolio
1 DCTH DELCATH SYS INC $29.0M 14.1%
2 VSTM VERASTEM INC $15.9M 7.75%
3 XERS XERIS BIOPHARMA HOLDINGS INC $13.7M 6.66%
4 MYO MYOMO INC $13.0M 6.32%
5 IDYA IDEAYA BIOSCIENCES INC $11.5M 5.58%
6 FENC FENNEC PHARMACEUTICALS INC $10.9M 5.28%
7 URGN UROGEN PHARMA LTD $10.5M 5.11%
8 OCUL OCULAR THERAPEUTIX INC $8.9M 4.34%
9 ABEO ABEONA THERAPEUTICS INC $8.6M 4.18%
10 REPL REPLIMUNE GROUP INC $8.3M 4.03%
11 VRDN VIRIDIAN THERAPEUTICS INC $8.0M 3.9%
12 MDWD MEDIWOUND LTD $7.9M 3.83%
13 SVRA SAVARA INC $7.4M 3.58%
14 VRNA VERONA PHARMA PLC $6.3M 3.09%
15 NSPR INSPIREMD INC $6.1M 2.98%
16 CYBN CYBIN INC $5.1M 2.5%
17 NUVB NUVATION BIO INC $4.3M 2.1%
18 PROF PROFOUND MED CORP $4.0M 1.96%
19 TRVI TREVI THERAPEUTICS INC $3.9M 1.87%
20 PHVS PHARVARIS N V $3.5M 1.71%

Values as reported on the Q1 2025 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings